This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bulfone-Paus, S. Articles by Kunzendorf, U. Search for Related Content PubMed Articles by Bulfone-Paus, S. Articles by Kunzendorf, U.

Vaccination with Tumor Cells Engineered to Secrete Interleukin 2-Immunoglobulin G Fusion Protein Induces Tumor Rejection¹

Institute of Immunology [S. B-P., H. v. B., D. U., T. P.], Departments of Ophthalmology [J. W.], Internal Medicine [M. N.], and Urology [H. K.], University Hospital Benjamin Franklin, Free University, 12200 Berlin, Germany; Department of Dermatology Charité, Humboldt University, Berlin, Germany [R. R. and R. P.]; and Department of Internal Medicine IV, Friedrich-Alexander-University 91054, Erlangen, Germany [U. K.]

Here we provide proof that the injection of tumor cells engineered to secrete interleukin 2 (IL-2)-IgG chimeric proteins locally induces potent antitumor responses, which are more effective than tumor transfection with IL-2 alone. Murine plasmacytoma cells (J558L) were stably transfected with DNA coding for a human IL-2-IgG1 or a murine IL-2-IgG2b fusion protein and were injected s.c. into syngeneic BALB/c mice. Evaluation of tumor growth and rejection patterns showed that IL-2-IgG secretion by transfected J558L tumor cells induced their rejection in all animals tested, similar to the rejection of J558L cells engineered to secrete IL-2 alone, whereas treatment with parental cells was lethal. However, mice treated with IL-2-IgG-secreting J558L cells (human IL-2-IgG1 and murine IL-2-IgG2b) exhibited a significantly stronger tumor immunity against a later challenge with parental J558L cells than mice treated with IL-2-secreting tumor cells.

¹ This study was supported in part by Grant SFB 506/C5 from the Deutsche Forschungsgemeinschaft (to S. B-P. and T. P.).

² To whom requests for reprints should be addressed, at Institute of Immunology, UKBF, FU Berlin, Hindenburgdamm 30, D-12200 Berlin, Germany. Phone: 49-30-84453639; Fax: 49-30-84454613; E-mail: bulfone@zedat.fu-berlin.de.

Received 3/ 9/98. Accepted 5/15/98.